Recent CMMB News
- Chemomab Therapeutics to Participate in Oppenheimer 35th Annual Healthcare Life Sciences Conference • GlobeNewswire Inc. • 02/03/2025 12:00:00 PM
- Chemomab to Participate in Oppenheimer’s Movers in Rare Disease Summit • GlobeNewswire Inc. • 12/03/2024 12:00:00 PM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 12/02/2024 09:22:12 PM
- Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] • Edgar (US Regulatory) • 11/29/2024 08:04:59 PM
- Form SC 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 11/21/2024 03:59:28 PM
- Oral Presentation at AASLD The Liver Meeting® 2024 Highlights Broad Clinical Activity of Chemomab’s CM-101 Across Multiple Biomarkers and Its Disease-Modifying Potential in Primary Sclerosing Cholangitis • GlobeNewswire Inc. • 11/19/2024 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/18/2024 09:19:07 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/15/2024 09:05:26 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/14/2024 12:00:10 PM
- Chemomab Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 11/14/2024 12:00:00 PM
- Chemomab Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Business Update • GlobeNewswire Inc. • 10/30/2024 11:00:00 AM
- Chemomab Therapeutics Announces Late-Breaking Oral Presentation of CM-101 Phase 2 Results in Primary Sclerosing Cholangitis at AASLD The Liver Meeting® 2024 • GlobeNewswire Inc. • 10/15/2024 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 10/11/2024 08:01:11 PM
- Chemomab Therapeutics to Present at October 2024 Investor Conferences • GlobeNewswire Inc. • 10/01/2024 11:00:00 AM
- Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] • Edgar (US Regulatory) • 09/16/2024 08:34:03 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/12/2024 08:56:36 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 09/09/2024 10:16:11 AM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 09/09/2024 04:15:09 AM
- Chemomab Therapeutics to Present at September 2024 Investor Conferences • GlobeNewswire Inc. • 08/28/2024 11:00:00 AM
- Form F-3 - Registration statement by foreign private issuers • Edgar (US Regulatory) • 08/23/2024 08:08:08 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/21/2024 11:00:21 AM
- Chemomab Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 08/21/2024 11:00:00 AM
- Chemomab Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Business Update • GlobeNewswire Inc. • 08/12/2024 11:00:00 AM
- Chemomab Therapeutics Announces Closing of $10 Million Private Placement • GlobeNewswire Inc. • 07/30/2024 01:00:00 PM
COEPTIS Announces the Launch of COEP Venture Group to Invest in AI, RPA, and AI Agent Startups • COEP • Feb 13, 2025 9:10 AM
Unitronix Corp. to Report Over 300% Gains in Cryptocurrency Assets • UTRX • Feb 13, 2025 7:15 AM
Hivello Token ($HVLO) now Live • MATE • Feb 11, 2025 9:27 AM
Animoca Brands leads Hivello funding round ahead of Token Listing • MATEF • Feb 10, 2025 10:20 AM
51 Labs Expands Sports Nutrition Line with Five New Innovative Products, Company in final phase of name and ticker symbol change • CAFI • Feb 10, 2025 9:00 AM
UAV Corp. Expanding in the Global UAV Market, Projected to Exceed $58 Billion by 2027, with Increasing Government and Commercial Sector Adoption • UMAV • Feb 6, 2025 8:30 AM